

# Bartolome R Celli

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5873063/bartolome-r-celli-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

359  
papers

30,466  
citations

79  
h-index

172  
g-index

398  
ext. papers

36,549  
ext. citations

8  
avg, IF

6.94  
L-index

#	Paper	IF	Citations
359	The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 1005-12	59.2	2702
358	Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 775-89	59.2	2457
357	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 557-582	10.2	1682
356	A 4-year trial of tiotropium in chronic obstructive pulmonary disease. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 1543-54	59.2	1658
355	American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2006</b> , 173, 1390-413	10.2	1361
354	Characterisation of COPD heterogeneity in the ECLIPSE cohort. <i>Respiratory Research</i> , <b>2010</b> , 11, 122	7.3	752
353	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	722
352	Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 186, 155-61	10.2	716
351	Chronic obstructive pulmonary disease phenotypes: the future of COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 182, 598-604	10.2	678
350	Changes in forced expiratory volume in 1 second over time in COPD. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1184-92	59.2	654
349	Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 111-22	59.2	595
348	Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2008</b> , 178, 332-8	10.2	566
347	Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. <i>PLoS ONE</i> , <b>2012</b> , 7, e37483	3.7	521
346	Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 182, 325-31	10.2	433
345	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>European Respiratory Journal</i> , <b>2017</b> , 49,	13.6	398
344	Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2005</b> , 171, 591-7	10.2	394
343	Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. <i>Lancet, The</i> , <b>2009</b> , 374, 1171-8 <sup>0</sup>	40	365

342	Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 185, 1065-72	10.2	288
341	Chronic obstructive pulmonary disease. <i>Nature Reviews Disease Primers</i> , <b>2015</b> , 1, 15076	51.1	270
340	Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. <i>Lancet, The</i> , <b>2016</b> , 387, 1817-26	4.0	263
339	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Archivos De Bronconeumologia</i> , <b>2017</b> , 53, 128-149	0.7	247
338	Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. <i>Respiratory Medicine</i> , <b>2013</b> , 107, 1376-84	4.6	243
337	Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. <i>Respiratory Research</i> , <b>2009</b> , 10, 59	7.3	234
336	Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. <i>Chest</i> , <b>2000</b> , 118, 1582-90	5.3	232
335	What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. <i>European Respiratory Journal</i> , <b>2016</b> , 48, 664-73	13.6	229
334	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Respirology</i> , <b>2017</b> , 22, 575-601	3.6	228
333	Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. <i>Chest</i> , <b>2003</b> , 124, 1743-8	5.3	226
332	Association Between Interstitial Lung Abnormalities and All-Cause Mortality. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 672-81	27.4	209
331	Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2009</b> , 180, 948-55	10.2	209
330	Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 187, 382-6	10.2	206
329	Lung cancer in patients with chronic obstructive pulmonary disease-- incidence and predicting factors. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 184, 913-9	10.2	205
328	Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. <i>Chest</i> , <b>2009</b> , 136, 1456-1465	5.3	202
327	Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. <i>Chest</i> , <b>2008</b> , 134, 746-752	5.3	199
326	The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. <i>Lancet Respiratory Medicine, the</i> , <b>2013</b> , 1, 129-36	35.1	183
325	Gender and COPD in patients attending a pulmonary clinic. <i>Chest</i> , <b>2005</b> , 128, 2012-6	5.3	182

324	The 6-min walk distance, peak oxygen uptake, and mortality in COPD. <i>Chest</i> , <b>2007</b> , 132, 1778-85	5.3	180
323	Impact of COPD exacerbations on patient-centered outcomes. <i>Chest</i> , <b>2007</b> , 131, 696-704	5.3	172
322	Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. <i>Chest</i> , <b>2006</b> , 130, 647-56	5.3	171
321	Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. <i>Chest</i> , <b>2002</b> , 121, 1092-8	5.3	171
320	Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. <i>Chest</i> , <b>2015</b> , 147, 894-942	5.3	169
319	Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. <i>Journal of the American Medical Directors Association</i> , <b>2012</b> , 13, 291-7	5.9	167
318	The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 184, 1015-21	10.2	155
317	Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. <i>Respiratory Medicine</i> , <b>2010</b> , 104, 849-57	4.6	148
316	Cardiovascular events in patients with COPD: TORCH study results. <i>Thorax</i> , <b>2010</b> , 65, 719-25	7.3	142
315	Profiling serum biomarkers in patients with COPD: associations with clinical parameters. <i>Thorax</i> , <b>2007</b> , 62, 595-601	7.3	140
314	Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. <i>European Respiratory Journal</i> , <b>2013</b> , 42, 636-46	13.6	139
313	An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2015</b> , 191, e4-e27	10.2	137
312	Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1257-1266	59.2	136
311	Gene expression profiling of human lung tissue from smokers with severe emphysema. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2004</b> , 31, 601-10	5.7	136
310	Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 183, 1129-37	10.2	135
309	Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2004</b> , 1, 303-12	2	133
308	Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. <i>Chest</i> , <b>2014</b> , 145, 981-991	5.3	129
307	Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey. <i>American Journal of Medicine</i> , <b>2005</b> , 118, 1364-72	2.4	125

306	Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 183, 317-22	10.2	122
305	Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. <i>Thorax</i> , <b>2014</b> , 69, 718-23	7.3	118
304	Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2014</b> , 189, 1022-30	10.2	117
303	Predictors of mortality in COPD. <i>Respiratory Medicine</i> , <b>2010</b> , 104, 773-9	4.6	117
302	Markers of disease severity in chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2006</b> , 19, 189-99	3.5	112
301	C-reactive protein levels and survival in patients with moderate to very severe COPD. <i>Chest</i> , <b>2008</b> , 133, 1336-1343	5.3	109
300	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , <b>2015</b> , 45, 879-905	13.6	107
299	Biological lung volume reduction: a new bronchoscopic therapy for advanced emphysema. <i>Chest</i> , <b>2007</b> , 131, 1108-13	5.3	104
298	Impact and prevention of severe exacerbations of COPD: a review of the evidence. <i>International Journal of COPD</i> , <b>2017</b> , 12, 2891-2908	3	102
297	Inhaled corticosteroids in COPD: friend or foe?. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	102
296	Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification. <i>Chest</i> , <b>2013</b> , 143, 694-702	5.3	101
295	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. <i>Lancet Respiratory Medicine</i> , <b>2015</b> , 3, 443-50	35.1	98
294	Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 51-57	10.2	97
293	Prediction of risk of COPD exacerbations by the BODE index. <i>Respiratory Medicine</i> , <b>2009</b> , 103, 373-8	4.6	97
292	Longitudinal change in the BODE index predicts mortality in severe emphysema. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2008</b> , 178, 491-9	10.2	97
291	Benralizumab for the Prevention of COPD Exacerbations. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1023-1034	59.2	94
290	COPD comorbidities network. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 640-50	13.6	94
289	At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 1540-1551	10.2	94

288	Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. <i>Annals of the American Thoracic Society</i> , <b>2015</b> , 12, 303-12	4.7	93
287	Predictors of Survival in COPD: more than just the FEV1. <i>Respiratory Medicine</i> , <b>2008</b> , 102 Suppl 1, S27-35	4.6	92
286	Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. <i>Chest</i> , <b>2007</b> , 131, 37-43	5.3	89
285	Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 186, 1238-47	10.2	88
284	Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. <i>Respiratory Medicine</i> , <b>2011</b> , 105, 580-7	4.6	87
283	Update on the management of COPD. <i>Chest</i> , <b>2008</b> , 133, 1451-1462	5.3	87
282	Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	84
281	Protective role for club cell secretory protein-16 (CC16) in the development of COPD. <i>European Respiratory Journal</i> , <b>2015</b> , 45, 1544-56	13.6	79
280	Functional Studies of Single-Nucleotide Polymorphisms Suggest Heterogeneity in Chronic Obstructive Pulmonary Disease due to Susceptibility of Different Cell Types. <i>Annals of the American Thoracic Society</i> , <b>2018</b> , 15, S285-S285	4.7	78
279	Multicomponent indices to predict survival in COPD: the COCOMICS study. <i>European Respiratory Journal</i> , <b>2013</b> , 42, 323-32	13.6	70
278	Gender associated differences in determinants of quality of life in patients with COPD: a case series study. <i>Health and Quality of Life Outcomes</i> , <b>2006</b> , 4, 72	3	70
277	The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. <i>European Respiratory Journal</i> , <b>2013</b> , 41, 1017-22	13.6	65
276	Benefits of Long-Term Pulmonary Rehabilitation Maintenance Program in Patients with Severe Chronic Obstructive Pulmonary Disease. Three-Year Follow-up. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 622-629	10.2	64
275	Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. <i>Thorax</i> , <b>2014</b> , 69, 799-804	7.3	63
274	COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs? (2017 Grover Conference Series). <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045894018758528	2.7	61
273	B Cell-Activating Factor. An Orchestrator of Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2015</b> , 192, 695-705	10.2	61
272	Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. <i>Respiratory Care</i> , <b>2006</b> , 51, 1120-4	2.1	61
271	Bronchodilator reversibility in COPD. <i>Chest</i> , <b>2011</b> , 140, 1055-1063	5.3	60

270	Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 182, 1004-10	10.2	59
269	Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. <i>Respiratory Medicine</i> , <b>2010</b> , 104, 1495-504	4.6	58
268	The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2016</b> , 194, 1483-1493	10.2	57
267	The COPD Biomarker Qualification Consortium (CBQC). <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2013</b> , 10, 367-77	2	57
266	Improving lung health in low-income and middle-income countries: from challenges to solutions. <i>Lancet, The</i> , <b>2021</b> , 397, 928-940	4.0	57
265	Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. <i>Respiratory Medicine</i> , <b>2015</b> , 109, 1138-46	4.6	56
264	Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 1000-1011	10.2	56
263	Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. <i>Clinical Respiratory Journal</i> , <b>2011</b> , 5, 44-9	1.7	55
262	Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. <i>Respiratory Research</i> , <b>2011</b> , 12, 71	7.3	54
261	Comparison of the 2017 and 2015 Global Initiative for Chronic Obstructive Lung Disease Reports. Impact on Grouping and Outcomes. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 463-469	10.2	53
260	What does endotyping mean for treatment in chronic obstructive pulmonary disease?. <i>Lancet, The</i> , <b>2017</b> , 390, 980-987	4.0	52
259	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Review</i> , <b>2015</b> , 24, 159-72	9.8	50
258	Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , <b>2005</b> , 99, 1546-54	4.6	49
257	Ventilatory drive at rest and perception of exertional dyspnea in severe COPD. <i>Chest</i> , <b>1999</b> , 115, 1293-300	9.3	49
256	Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 199, 1195-1204	10.2	49
255	DNA methylation profiling in human lung tissue identifies genes associated with COPD. <i>Epigenetics</i> , <b>2016</b> , 11, 730-739	5.7	48
254	Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use. <i>Chest</i> , <b>2014</b> , 145, 695-703	5.3	46
253	Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study. <i>Respiratory Medicine</i> , <b>2013</b> , 107, 702-7	4.6	46

252	Executive summary: prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. <i>Chest</i> , <b>2015</b> , 147, 883-893	5.3	44
251	COPD: time to improve its taxonomy?. <i>ERJ Open Research</i> , <b>2018</b> , 4,	3.5	43
250	Prognostic assessment in COPD: health related quality of life and the BODE index. <i>Respiratory Medicine</i> , <b>2011</b> , 105, 916-21	4.6	43
249	Genome-wide association analysis of body mass in chronic obstructive pulmonary disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2011</b> , 45, 304-10	5.7	43
248	Identification of COPD Patients at High Risk for Lung Cancer Mortality Using the COPD-LUCSS-DLCO. <i>Chest</i> , <b>2016</b> , 149, 936-42	5.3	43
247	Club Cell Protein 16 (CC16) Augmentation: A Potential Disease-modifying Approach for Chronic Obstructive Pulmonary Disease (COPD). <i>Expert Opinion on Therapeutic Targets</i> , <b>2016</b> , 20, 869-83	6.4	42
246	Gender and respiratory factors associated with dyspnea in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , <b>2007</b> , 8, 18	7.3	42
245	Handgrip weakness and mortality risk in COPD: a multicentre analysis. <i>Thorax</i> , <b>2016</b> , 71, 86-7	7.3	41
244	Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial. <i>Chest</i> , <b>2013</b> , 144, 490-497	5.3	41
243	Lung volume reduction therapies for advanced emphysema: an update. <i>Chest</i> , <b>2010</b> , 138, 407-17	5.3	41
242	Roger s. Mitchell lecture. Chronic obstructive pulmonary disease phenotypes and their clinical relevance. <i>Proceedings of the American Thoracic Society</i> , <b>2006</b> , 3, 461-5		41
241	Differences in cardiopulmonary exercise test results by American Thoracic Society/European Respiratory Society-Global Initiative for Chronic Obstructive Lung Disease stage categories and gender. <i>Chest</i> , <b>2007</b> , 132, 1204-11	5.3	41
240	Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. <i>Respirology</i> , <b>2011</b> , 16, 825-35	3.6	39
239	Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism. <i>Proceedings of the American Thoracic Society</i> , <b>2006</b> , 3, 58-65		39
238	Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. <i>European Respiratory Journal</i> , <b>2018</b> , 51,	13.6	38
237	Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 881-888	10.2	38
236	Sexually-dimorphic targeting of functionally-related genes in COPD. <i>BMC Systems Biology</i> , <b>2014</b> , 8, 118	3.5	38
235	Gender differences in plasma biomarker levels in a cohort of COPD patients: a pilot study. <i>PLoS ONE</i> , <b>2011</b> , 6, e16021	3.7	38



234	Opportunities and challenges in the genetics of COPD 2010: an International COPD Genetics Conference report. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2011</b> , 8, 121-35	2	38
233	Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. <i>International Journal of COPD</i> , <b>2018</b> , 13, 3971-3981	3	38
232	Different dyspnoea perception in COPD patients with frequent and infrequent exacerbations. <i>Thorax</i> , <b>2017</b> , 72, 117-121	7.3	35
231	A simple algorithm for the identification of clinical COPD phenotypes. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	35
230	Deterioration of Limb Muscle Function during Acute Exacerbation of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 433-449	10.2	35
229	Chronic Obstructive Pulmonary Disease (COPD) as a disease of early aging: Evidence from the EpiChron Cohort. <i>PLoS ONE</i> , <b>2018</b> , 13, e0193143	3.7	35
228	Disease progression in young patients with COPD: rethinking the Fletcher and Peto model. <i>European Respiratory Journal</i> , <b>2014</b> , 44, 324-31	13.6	35
227	Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study. <i>PLoS ONE</i> , <b>2014</b> , 9, e89866	3.7	35
226	Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. <i>Lancet Respiratory Medicine</i> , <b>2020</b> , 8, 158-170	35.1	35
225	Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. <i>Heart</i> , <b>2017</b> , 103, 1536-1542	5.1	34
224	It's more than low BMI: prevalence of cachexia and associated mortality in COPD. <i>Respiratory Research</i> , <b>2019</b> , 20, 100	7.3	34
223	Changes in body composition in patients with chronic obstructive pulmonary disease: do they influence patient-related outcomes?. <i>Annals of Nutrition and Metabolism</i> , <b>2013</b> , 63, 239-47	4.5	34
222	Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 47-55	10.2	34
221	Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 1126-1137	15.1	31
220	Perception of symptoms and quality of life - comparison of patients' and physicians' views in the COPD MIRROR study. <i>International Journal of COPD</i> , <b>2017</b> , 12, 2189-2196	3	31
219	Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 202, e74-e87	10.2	31
218	Effect of a single exacerbation on decline in lung function in COPD. <i>Respiratory Medicine</i> , <b>2017</b> , 128, 85-91	16	30
217	Telomere shortening and accelerated aging in COPD: findings from the BODE cohort. <i>Respiratory Research</i> , <b>2017</b> , 18, 59	7.3	30

216	Comorbidity Distribution, Clinical Expression and Survival in COPD Patients with Different Body Mass Index. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2014</b> , 1, 229-238	2.7	30
215	The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases. <i>Chest</i> , <b>2012</b> , 142, 1027-1034	5.3	29
214	Prognostic assessment in COPD without lung function: the B-AE-D indices. <i>European Respiratory Journal</i> , <b>2016</b> , 47, 1635-44	13.6	29
213	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Archivos De Bronconeumologia</i> , <b>2017</b> , 53, 128-149	0.7	27
212	Longitudinal assessment in COPD patients: multidimensional variability and outcomes. <i>European Respiratory Journal</i> , <b>2014</b> , 43, 745-53	13.6	26
211	Time to desaturation in the 6-min walking distance test predicts 24-hour oximetry in COPD patients with a PO <sub>2</sub> between 60 and 70mmHg. <i>Respiratory Medicine</i> , <b>2008</b> , 102, 1026-32	4.6	26
210	From GOLD 0 to Pre-COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 414-423	30.2	26
209	Spirometric variability in smokers: transitions in COPD diagnosis in a five-year longitudinal study. <i>Respiratory Research</i> , <b>2016</b> , 17, 147	7.3	25
208	Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmonary disease: correlation with clinical parameters. <i>Proceedings of the American Thoracic Society</i> , <b>2006</b> , 3, 465-6		25
207	Cough and phlegm are important predictors of health status in smokers without COPD. <i>Chest</i> , <b>2002</b> , 121, 1427-33	5.3	25
206	Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , <b>2015</b> , 10, 549-64	3	24
205	A novel nonhuman primate model of cigarette smoke-induced airway disease. <i>American Journal of Pathology</i> , <b>2015</b> , 185, 741-55	5.8	23
204	The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , <b>2013</b> , 7, 57-64	3.8	23
203	Natural history of COPD: gaps and opportunities. <i>ERJ Open Research</i> , <b>2017</b> , 3,	3.5	23
202	Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. <i>Respiratory Medicine</i> , <b>2011</b> , 105, 1176-88	4.6	23
201	Native American ancestry, lung function, and COPD in Costa Ricans. <i>Chest</i> , <b>2014</b> , 145, 704-710	5.3	22
200	Chronic obstructive pulmonary disease and lung cancer: common pathogenesis, shared clinical challenges. <i>Proceedings of the American Thoracic Society</i> , <b>2012</b> , 9, 74-9		22
199	A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. <i>Clinical Therapeutics</i> , <b>2003</b> , 25, 542-57	3.5	22

198	Systemic biomarkers in the evaluation and management of COPD patients: are we getting closer to clinical application?. <i>Current Drug Targets</i> , <b>2013</b> , 14, 177-91	3	22
197	Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. <i>Respiratory Medicine</i> , <b>2017</b> , 131, 27-34	4.6	21
196	Clinical Features of Smokers With Radiological Emphysema But Without Airway Limitation. <i>Chest</i> , <b>2017</b> , 151, 358-365	5.3	21
195	Lung reduction surgery in severe COPD decreases central drive and ventilatory response to CO <sub>2</sub> . <i>Chest</i> , <b>1997</b> , 112, 902-6	5.3	21
194	Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. <i>Respiratory Medicine</i> , <b>2016</b> , 119, 87-95	4.6	21
193	Predictors of mortality in chronic obstructive pulmonary disease. <i>Clinics in Chest Medicine</i> , <b>2007</b> , 28, 515-24, v	5.3	20
192	Change in the BODE index reflects disease modification in COPD: lessons from lung volume reduction surgery. <i>Chest</i> , <b>2006</b> , 129, 835-6	5.3	20
191	Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial. <i>BMJ Open Respiratory Research</i> , <b>2019</b> , 6, e000431	5.6	18
190	Adverse health consequences in COPD patients with rapid decline in FEV <sub>1</sub> --evidence from the UPLIFT trial. <i>Respiratory Research</i> , <b>2011</b> , 12, 129	7.3	18
189	Inhalation Technique Errors with Metered-Dose Inhalers Among Patients with Obstructive Lung Diseases: A Systematic Review and Meta-Analysis of U.S. Studies. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , <b>2019</b> , 6, 267-280	2.7	18
188	Cigarette smoking and response to inhaled corticosteroids in COPD. <i>European Respiratory Journal</i> , <b>2018</b> , 51,	13.6	17
187	Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. <i>European Heart Journal</i> , <b>2018</b> , 39, 3128-3134	9.5	17
186	Premature discontinuation during the UPLIFT study. <i>Respiratory Medicine</i> , <b>2011</b> , 105, 1523-30	4.6	17
185	Sex differences between women and men with COPD: A new analysis of the 3CIA study. <i>Respiratory Medicine</i> , <b>2020</b> , 171, 106105	4.6	17
184	Supplementation with Qter and Creatine improves functional performance in COPD patients on long term oxygen therapy. <i>Respiratory Medicine</i> , <b>2018</b> , 142, 86-93	4.6	16
183	The Challenge of Controlling the COPD Epidemic: Unmet Needs. <i>American Journal of Medicine</i> , <b>2018</b> , 131, 1-6	2.4	16
182	Machine Learning and Prediction of All-Cause Mortality in COPD. <i>Chest</i> , <b>2020</b> , 158, 952-964	5.3	15
181	Pharmacological Therapy of COPD: Reasons for Optimism. <i>Chest</i> , <b>2018</b> , 154, 1404-1415	5.3	15

180	Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. <i>Respiratory Medicine</i> , <b>2013</b> , 107, 1904-11	4.6	15
179	Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 1288-1298	35.1	15
178	Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis. <i>Chronic Respiratory Disease</i> , <b>2020</b> , 17, 1479973119901234	3	14
177	βBlocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT. <i>Annals of the American Thoracic Society</i> , <b>2018</b> , 15, 608-614	4.7	14
176	Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. <i>BMC Medicine</i> , <b>2018</b> , 16, 33	11.4	14
175	Precision medicine in COPD exacerbations. <i>Lancet Respiratory Medicine</i> , <b>2018</b> , 6, 657-659	35.1	14
174	Obstructive lung disease in Mexican Americans and non-Hispanic whites: an analysis of diagnosis and survival in the National Health and Nutritional Examination Survey III Follow-up Study. <i>Chest</i> , <b>2014</b> , 145, 282-289	5.3	14
173	Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , <b>2012</b> , 13, 66	7.3	14
172	Plasma metabolomics and clinical predictors of survival differences in COPD patients. <i>Respiratory Research</i> , <b>2019</b> , 20, 219	7.3	13
171	Epicardial adipose tissue in patients with chronic obstructive pulmonary disease. <i>PLoS ONE</i> , <b>2013</b> , 8, e65593	5.93	13
170	Future perspectives in COPD. <i>Respiratory Medicine</i> , <b>2005</b> , 99 Suppl B, S41-8	4.6	13
169	The Course of Lung Function in Middle-aged Heavy Smokers: Incidence and Time to Early Onset of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 1449-1451	10.2	12
168	Airflow reversibility and long-term outcomes in patients with COPD without comorbidities. <i>Respiratory Medicine</i> , <b>2014</b> , 108, 1180-8	4.6	12
167	Chronic Obstructive Pulmonary Disease in Hispanics. A 9-Year Update. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 15-21	10.2	12
166	Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT trial. <i>Respiratory Research</i> , <b>2018</b> , 19, 196	7.3	12
165	Metformin: Experimental and Clinical Evidence for a Potential Role in Emphysema Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 204, 651-666	10.2	12
164	Telomere length, COPD and emphysema as risk factors for lung cancer. <i>European Respiratory Journal</i> , <b>2017</b> , 49,	13.6	11
163	Clinical and prognostic heterogeneity of C and D GOLD groups. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 250-4	13.6	11

162	Low plasma CC16 levels in smokers are associated with a higher risk for chronic bronchitis. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1501-3	13.6	11
161	FEV is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease. <i>International Journal of COPD</i> , <b>2020</b> , 15, 1135-1142	3	11
160	The EXACT-Pro: measuring exacerbations of COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 183, 287-8	10.2	11
159	Identification of Barriers to Influenza Vaccination in Patients with Chronic Obstructive Pulmonary Disease: Analysis of the 2012 Behavioral Risk Factors Surveillance System. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2016</b> , 3, 620-627	2.7	11
158	Multimorbidity in Patients with Chronic Obstructive Pulmonary Disease. <i>Clinics in Chest Medicine</i> , <b>2020</b> , 41, 405-419	5.3	11
157	Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. <i>Respirology</i> , <b>2021</b> , 26, 532-551	3.6	11
156	Prognostic Validation Using GesEPOC 2017 Severity Criteria. <i>Archivos De Bronconeumologia</i> , <b>2019</b> , 55, 409-413	0.7	10
155	Continuous fat-free mass decline in COPD: fact or fiction?. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1496-1503	8.3.6	10
154	Agreement between a simple dyspnea-guided treatment algorithm for stable COPD and the GOLD guidelines: a pilot study. <i>International Journal of COPD</i> , <b>2016</b> , 11, 1217-22	3	10
153	Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 689-698	10.2	10
152	An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 204, 1251-1258	10.2	10
151	Pulmonary arterial enlargement predicts long-term survival in COPD patients. <i>PLoS ONE</i> , <b>2018</b> , 13, e0195640	5.640	9
150	Assessment of five different guideline indication criteria for spirometry, including modified GOLD criteria, in order to detect COPD: data from 5,315 subjects in the PLATINO study. <i>Npj Primary Care Respiratory Medicine</i> , <b>2014</b> , 24, 14075	3.2	9
149	Prospective comparison of non-invasive risk markers of major cardiovascular events in COPD patients. <i>Respiratory Research</i> , <b>2017</b> , 18, 175	7.3	9
148	Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis. <i>BMC Pulmonary Medicine</i> , <b>2015</b> , 15, 145	3.5	9
147	Characterizing functional lung heterogeneity in COPD using reference equations for CT scan-measured lobar volumes. <i>Chest</i> , <b>2013</b> , 143, 1607-1617	5.3	9
146	Prognostic assessment of patients with COPD. <i>Lancet, The</i> , <b>2009</b> , 374, 1885; author reply 1886-7	40	9
145	The most beautiful COPD chart in the world: all together to end COPD!. <i>European Respiratory Journal</i> , <b>2019</b> , 54,	13.6	8

144	Six-minute walking distance in women with COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2011</b> , 8, 300-5	2	8
143	Pulmonary rehabilitation for COPD. A practical approach for improving ventilatory conditioning. <i>Postgraduate Medicine</i> , <b>1998</b> , 103, 159-60, 167-8, 173-6	3.7	8
142	Differences in Health-Related Quality of Life Between New Mexican Hispanic and Non-Hispanic White Smokers. <i>Chest</i> , <b>2016</b> , 150, 869-876	5.3	8
141	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. <i>Annals of the American Thoracic Society</i> , <b>2019</b> , 16, 29-39	4.7	8
140	The club cell and its protein, CC16: time to shine. <i>Lancet Respiratory Medicine</i> , <b>2013</b> , 1, 757-9	35.1	7
139	Treatment Trials in Young Patients with COPD and Pre-COPD Patients: Time to Move Forward. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> ,	10.2	7
138	Is COPD a Progressive Disease? A Long Term Bode Cohort Observation. <i>PLoS ONE</i> , <b>2016</b> , 11, e0151856	3.7	7
137	The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCs randomised controlled trial. <i>European Respiratory Journal</i> , <b>2021</b> , 57,	13.6	7
136	Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT <sup>®</sup> trial. <i>Respiratory Research</i> , <b>2016</b> , 17, 48	7.3	6
135	Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. <i>European Respiratory Journal</i> , <b>2021</b> , 57,	13.6	6
134	Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting $\beta_2$ -agonists. <i>Journal of Medical Economics</i> , <b>2016</b> , 19, 11-20	2.4	5
133	Smoking Pattern in Men and Women: A Possible Contributor to Sex Differences in Smoke-related Lung Diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 202, 1048-1051	10.2	5
132	Maximal Oxygen Uptake--Risk Predictor of NSCLC Resection in Patients With Comorbid Emphysema: Lessons From NETT. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , <b>2015</b> , 27, 225-31	1.7	5
131	Effects of Tiotropium on Exacerbations in Patients with COPD with Low or High Risk of Exacerbations: A Post-Hoc Analysis from the 4-Year UPLIFT <sup>®</sup> Trial. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2015</b> , 2, 122-130	2.7	5
130	Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment. <i>International Journal of COPD</i> , <b>2019</b> , 14, 1019-1031	3	4
129	External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2019</b> , 16, 8-17	2	4
128	Recommendations for the early diagnosis of COPD: the AIMAR view. <i>Multidisciplinary Respiratory Medicine</i> , <b>2015</b> , 10, 6	3	4
127	Shorter telomeres in non-smoking patients with airflow limitation. <i>Respiratory Medicine</i> , <b>2018</b> , 138, 123-128	12.8	4

126	COPD (confusion over proper diagnosis) in the zone of maximum uncertainty. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1525-6	13.6	4
125	Comparison of arterial and venous blood biomarker levels in chronic obstructive pulmonary disease. <i>F1000Research</i> , <b>2013</b> , 2, 114	3.6	4
124	COPD heterogeneity: gender differences in the multidimensional BODE index. <i>International Journal of COPD</i> , <b>2007</b> , 2, 151-5	3	4
123	Urgent need of a management plan for survivors of COVID-19. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	4
122	Prevalence of paradoxical bronchoconstriction after inhaled albuterol. <i>Respiratory Medicine</i> , <b>2018</b> , 141, 100-102	4.6	4
121	Clinical and Prognostic Impact of Low Diffusing Capacity for Carbon Monoxide Values in Patients With Global Initiative for Obstructive Lung Disease I COPD. <i>Chest</i> , <b>2021</b> , 160, 872-878	5.3	4
120	Impact of pre-enrolment medication use on clinical outcomes in SUMMIT. <i>ERJ Open Research</i> , <b>2019</b> , 5,	3.5	3
119	The Prevalence of Obstructive Lung Disease in a Lung Cancer Screening Cohort: Analysis of the National Lung Screening Trial-American College of Radiology Image Network Cohort. <i>Annals of the American Thoracic Society</i> , <b>2019</b> , 16, 641-644	4.7	3
118	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data. <i>ERJ Open Research</i> , <b>2020</b> , 6,	3.5	3
117	Inhaler device feature preferences among patients with obstructive lung diseases: A systematic review and meta-analysis. <i>Medicine (United States)</i> , <b>2020</b> , 99, e20718	1.8	3
116	The EASI model: A first integrative computational approximation to the natural history of COPD. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185502	3.7	3
115	Long-Acting $\beta$ Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 1641-1644	10.2	3
114	The effect of emphysema on readmission and survival among smokers with heart failure. <i>PLoS ONE</i> , <b>2018</b> , 13, e0201376	3.7	3
113	Health effects of the Federal Bureau of Prisons tobacco ban. <i>BMC Pulmonary Medicine</i> , <b>2012</b> , 12, 64	3.5	3
112	Predicting mortality in chronic obstructive pulmonary disease: chasing the "Holy Grail". <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2006</b> , 173, 1298-9	10.2	3
111	Proteinases and COPD349-366		3
110	New treatment strategies for COPD. Pairing the new with the tried and true. <i>Postgraduate Medicine</i> , <b>2005</b> , 117, 27-34	3.7	3
109	Effect of Tiotropium on Outcomes in Patients With COPD, Categorized Using the New GOLD Grading System: Results of the UPLIFT <sup>®</sup> Randomized Controlled Trial. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2015</b> , 2, 236-251	2.7	3

108	ADAM15 expression is increased in lung CD8 T cells, macrophages, and bronchial epithelial cells in patients with COPD and is inversely related to airflow obstruction. <i>Respiratory Research</i> , <b>2020</b> , 21, 188	7.3	3
107	Methods for a Seamless Transition From Tracheostomy to Spontaneous Breathing in Patients With COVID-19. <i>Respiratory Care</i> , <b>2020</b> , 65, 1773-1783	2.1	3
106	Somatotypes trajectories during adulthood and their association with COPD phenotypes. <i>ERJ Open Research</i> , <b>2020</b> , 6,	3.5	3
105	Spirometry: A practical lifespan predictor of global health and chronic respiratory and non-respiratory diseases. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 89, 3-9	3.9	3
104	Using the Peripheral Blood Eosinophil Count to Manage Patients with Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , <b>2019</b> , 16, 301-303	4.7	3
103	Exploring the Impact of Lung Cancer Screening on Lung Cancer Mortality of Smokers With Obstructive Lung Disease: Analysis of the NLST-ACRIN Cohort. <i>Archivos De Bronconeumologia</i> , <b>2021</b> , 57, 36-41	0.7	3
102	Natural Course of the Diffusing Capacity of the Lungs for Carbon Monoxide in COPD: Importance of Sex. <i>Chest</i> , <b>2021</b> , 160, 481-490	5.3	3
101	The BODECOST Index (BCI): a composite index for assessing the impact of COPD in real life. <i>Multidisciplinary Respiratory Medicine</i> , <b>2016</b> , 11, 10	3	2
100	Counterpoint: Should storefront clinics provide case finding and chronic care for COPD? No. <i>Chest</i> , <b>2014</b> , 145, 1193-1194	5.3	2
99	Women with chronic obstructive pulmonary disease: an emerging phenotype of the disease. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2009</b> , 6, 821-830		2
98	Economic Burden of COPD779-791		2
97	Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial. <i>ERJ Open Research</i> , <b>2021</b> , 7,	3.5	2
96	Predictors of Nebulized Arformoterol Treatment: A Retrospective Analysis of Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2019</b> , 16, 140-151	2	1
95	Regional differences in rate of FEV decline in COPD: lessons from SUMMIT. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	1
94	Metabolic and cardiorespiratory effects of decreasing lung hyperinflation with budesonide/formoterol in COPD: a randomized, double-crossover, placebo-controlled, multicenter trial. <i>Respiratory Research</i> , <b>2020</b> , 21, 26	7.3	1
93	A Historical Perspective of Pulmonary Rehabilitation <b>2018</b> , 3-18		1
92	Reply to Voelkel: Cigarette Smoke Is an Endothelial Cell Toxin. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 274-275	10.2	1
91	Expert Statement on the Single-Agent Use of Inhaled Bronchodilator in the Treatment of Stable Mild-Moderate Chronic Obstructive Pulmonary Disease. <i>Archivos De Bronconeumologia</i> , <b>2017</b> , 53, 574-582	0.7	1



90	Does pharmacotherapy reduce the rate of decline of lung function in COPD?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2009</b> , 179, 171; author reply 171-2	10.2	1
89	Bronchiectasis and COPD139-147		1
88	Exercise Limitations and Cardiopulmonary Exercise Testing in COPD40-62		1
87	The Natural History of COPD115-123		1
86	Lymphocytes269-274		1
85	Oxidants367-384		1
84	Cigarette Smoke-Induced Disease385-396		1
83	COPD and Air Pollution397-407		1
82	α1-Antitrypsin Deficiency447-459		1
81	Comorbidity569-576		1
80	Physiology and Pathobiology of the Lung Circulation75-79		1
79	Chemokines in COPD859-866		1
78	The use of multidimensional indices143-160		1
77	Triple Therapy Is Also Effective in Real-World When Used in Chronic Obstructive Pulmonary Disease Patients Who Are Frequent Exacerbators. <i>Respiration</i> , <b>2021</b> , 100, 93-95	3.7	1
76	Psoas Muscle Density Evaluated by Chest CT and Long-Term Mortality in COPD Patients. <i>Archivos De Bronconeumologia</i> , <b>2021</b> , 57, 533-539	0.7	1
75	Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT. <i>Annals of the American Thoracic Society</i> , <b>2021</b> ,	4.7	1
74	Pulmonary rehabilitation. <i>Israel Medical Association Journal</i> , <b>2003</b> , 5, 443-8	0.9	1
73	Novel concepts in the pharmacotherapy of chronic obstructive pulmonary disease. <i>Pneumologia i Alergologia Polska</i> , <b>2009</b> , 77, 82-90		1

72	Rapid decline in lung function in healthy adults predicts incident excess urinary albumin excretion later in life. <i>BMJ Open Respiratory Research</i> , <b>2017</b> , 4, e000194	5.6	o
71	A Delphi Consensus Document on the Use of Single-Inhaler Fixed-Dose Triple Therapies in COPD Patients. <i>International Journal of COPD</i> , <b>2020</b> , 15, 1801-1811	3	o
70	Optimal NIV Medicare Access Promotion: Patients With COPD: A Technical Expert Panel Report From the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society. <i>Chest</i> , <b>2021</b> , 160, e389-e397	5.3	o
69	Executive Summary: Optimal NIV Medicare Access Promotion: A Technical Expert Panel Report From the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society. <i>Chest</i> , <b>2021</b> , 160, 1808-1821	5.3	o
68	Exploring the Impact of Lung Cancer Screening on Lung Cancer Mortality of Smokers With Obstructive Lung Disease: Analysis of the NLST-ACRIN Cohort. <i>Archivos De Bronconeumologia</i> , <b>2021</b> , 57, 36-41	0.7	o
67	Reply: Controlled Clinical Trials and Real-Life Experience with Pulmonary Rehabilitation. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 196, 797	10.2	
66	Prognostic Validation Using GesEPOC 2017 Severity Criteria. <i>Archivos De Bronconeumologia</i> , <b>2019</b> , 55, 409-413	0.7	
65	Rebuttal from Dr. Celli. <i>Chest</i> , <b>2014</b> , 145, 1195-1196	5.3	
64	Expert Statement on the Single-Agent Use of Inhaled Bronchodilator in the Treatment of Stable Mild-Moderate Chronic Obstructive Pulmonary Disease. <i>Archivos De Bronconeumologia</i> , <b>2017</b> , 53, 574-582	0.7	
63	Is the Blood Eosinophil Count a Useful Biomarker in COPD? The devil is in the Details!. <i>Archivos De Bronconeumologia</i> , <b>2017</b> , 53, 415-416	0.7	
62	We must join forces in the battle against COPD. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1528	13.6	
61	Treatment of the Stable Patient with Chronic Obstructive Pulmonary Disease <b>2012</b> , 553-561		
60	Effect of Pharmacotherapy on Rate of Decline of FEV1 in the TORCH Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2009</b> , 179, 426-427	10.2	
59	Lung Volume Reduction in Patients with COPD: Physiological and Clinical Implications. <i>Current Respiratory Medicine Reviews</i> , <b>2008</b> , 4, 312-320	0.3	
58	Colour Plate Section 893-900		
57	Aerosols and Delivery Systems 481-498		
56	Anticholinergics in COPD 657-668		
55	The Physiology of Breathlessness 20-25		

54 The Physiology of Muscle26-39

53 Obliterative Bronchiolitis148-153

52 Monitoring and Outcomes181-188

51 Mucosal Immunity201-211

50 COPD and Pulmonary Surfactant212-218

49 The Macrophage and its Role in the Pathogenesis of COPD219-232

48 Eosinophils and COPD233-244

47 Airway Epithelial Defence, Repair and Regeneration245-254

46 The Role of the Neutrophil in the Pathogenesis of COPD255-268

45 Leukotrienes in COPD: The Unexploited Potential285-299

44 Cigarette Smoking, Emphysema and Lung Endothelium300-307

43 Mesenchymal Cells of the Lung308-316

42 Lung Development317-340

41 Animal Models341-348

40 Viruses in COPD408-418

39 Genetic Factors436-446

38 Body Weight and Systemic Effects460-466

37 Lung Connective Tissue467-480

36 Gastro-Oesophageal Reflux499-512

35 Upper Airway Diseases513-527

34 Acute Pulmonary Embolism528-537

33 Infection Management and Airflow Obstruction546-558

32 Mechanical Ventilation for Exacerbation of COPD559-568

31 Clinical Assessment of Control of Breathing63-74

30 Pulmonary Rehabilitation585-594

29 Social Support595-600

28 Long-Term Invasive Mechanical Ventilation601-607

27 Oxygen Therapy in COPD622-635

26 Surgical Therapy for COPD636-656

25  $\beta_2$ -Agonists669-684

24 Phosphodiesterase 4 Inhibitors in the Treatment of COPD708-727

23 Antibiotic Therapy in Patients with COPD728-746

22 Antioxidants747-755

21 Mucolytics for COPD756-768

20 End-Of-Life and Palliative Care for Patients with COPD769-778

19 Pharmacoepidemiology of COPD792-804

18 Social and Behavioural Impact of COPD - Research Opportunities 805-810

17 Guidelines 811-820

16 Protease Inhibitors 821-844

15 Retinoids 845-858

14 Sleep in Patients with COPD 80-89

13 The Physiology of Gas Exchange 102-114

12 The Physiology of Cough 90-101

11 COPD and Lung Cancer 538-545

10 Mucociliary Clearance 189-200

9 Structure-function Relationships: The Pathophysiology of Airflow Obstruction 1-19

8 A 62-year-old woman with chronic obstructive pulmonary disease. *JAMA - Journal of the American Medical Association*, **2003**, 290, 2721-9 27.4

7 Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASC Trial. *International Journal of COPD*, **2022**, 17, 273-282 3

6 The 7 Cardinal Sins of COPD in Spain. *Archivos De Bronconeumologia*, **2022**, 0.7

5 Network Analysis of Autopsy Diagnoses: Insights into the "Cause of Death" from Unbiased Disease Clustering. *Journal of Pathology Informatics*, **2018**, 9, 35 4.4

4 Management Guidelines for Chronic Obstructive Pulmonary Disease **2011**, 81-98

3 Reply to Thomson, to Neder ., and to Wouters. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 204, 112 10.2

2 Psoas Muscle Density Evaluated by Chest CT and Long-Term Mortality in COPD Patients. *Archivos De Bronconeumologia*, **2021**, 57, 533-533 0.7

1 Comorbidities in Patients With Chronic Obstructive Pulmonary Disease **2022**, 663-674

